Chemopreventive Effect of Curcumin, a Naturally Occurring Anti-Inflammatory Agent, during the Promotion/Progression Stages of Colon Cancer

Toshihiko Kawamori, Ronald Lubet, Vernon E. Steele, Gary J. Kelloff, Robert B. Kaskey, Chinthalapally V. Rao, and Bandaru S. Reddy


INTRODUCTION

Colorectal cancer, one of the leading causes of cancer deaths in both men and women in the United States, accounts for ~56,000 deaths annually (1). Although several epidemiological and laboratory studies suggest a relationship between large bowel cancer risk and dietary factors (2–4), there is increasing evidence that a high consumption of fruits and vegetables and intake of certain nonnutrients that are present in foods reduce the risk of colon carcinogenesis (5). Although risk reduction by nutritional intervention may not be sufficient to protect high-risk individuals against colon cancer development, an alternative or complementary effective approach for secondary prevention has been to identify the agents with chemopreventive potency and to evaluate them in high-risk individuals in combination with nutritional intervention (6–8).

It is noteworthy that the use of medicinal plants or their crude extracts in the prevention and/or treatment of several chronic diseases has been traditionally practiced in various different ethnic societies worldwide. Turmeric, the powdered rhizome of Curcuma longa L., has been used to treat a variety of inflammatory conditions and chronic diseases (9, 10); it is also used as coloring and flavoring additive to foods. Curcumin [Fig. 1; diferuloylmethane; 1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione], which has been identified as the major pigment in turmeric, possesses both anti-inflammatory (11–13) and antioxidant properties (14, 15). It has been demonstrated that topical application of curcumin inhibits benzo[a]pyrene-induced DNA adduct formation, and development of skin tumors as well as TPA3-induced epidermal DNA synthesis and tumor promotion in mouse skin (16–18). Curcumin has a strong inhibitory effect on cell proliferation in the HT-29 and HCT-15 human colon cancer cell lines (19). Importantly, dietary administration of curcumin during initiation and/or postinitiation periods significantly suppresses development of chemically induced forestomach, duodenal, and colon tumors in CF-1 mice (20); it also reduces formation of focal areas of dysplasia and aberrant crypt foci in the colon that are early preneoplastic lesions in rodents (21, 22). Pereira et al. (23) have reported that administration of 0.8 and 1.6% curcumin continuously during the initiation and postinitiation phases significantly inhibited development of AOM-induced adenocarcinomas in rats. We have shown that continuous dietary administration of 0.2% curcumin during the initiation and postinitiation stages significantly inhibited the incidence and multiplicity of AOM-induced colon adenocarcinomas and the tumor burden in F344 rats (24). Although all of the above studies clearly demonstrate the potential chemopreventive activity of curcumin during the initiation and postinitiation periods of colon carcinogenesis, there were no studies on the efficacy of this agent during the promotion/progression stage when the premalignant lesions would have developed. We deemed it important to show that curcumin treatment can be delayed after the carcinogen administration in experimental carcinogenesis and still be effective, so as to provide baseline knowledge for possible clinical use of this agent in secondary prevention of colon cancer in high-risk individuals, such as patients with colonic polyps.

Curcumin was shown to inhibit colon carcinogenesis during the postinitiation stage through the modulation of COX activity in the tumor tissue (24). COXs are involved in the synthesis of PGs, which have been shown to affect tumor growth (24), suggesting that effects on the arachidonic acid cascade by curcumin may play a role in its tumor-inhibitory activity. We and others have shown previously that several inhibitors of PG synthesis, such as aspirin, ibuprofen, sulindac, and piroxicam suppress colon carcinogenesis in laboratory animal model assays (25–28). Inhibition of colon carcinogenesis was consistently associated with a decrease in the activity of COX in colon...
CHEMOPREVENTIVE EFFECT OF CURCUMIN

Fig. 1. Chemical structure of curcumin [1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione].

Fig. 2. Experimental design for evaluation of the chemopreventive activity of curcumin against colon carcinogenesis. Groups of male F344 rats were fed the experimental diets containing 0 or 0.2% curcumin beginning 2 weeks prior to exposure to AOM, during treatment, and until termination (initiation and postinitiation stages). Additional groups of animals who were on control diet (0% curcumin) 2 weeks prior to exposure of AOM, during treatment, and until 14 weeks after AOM treatment were transferred to experimental diets containing 0.2 and 0.6% curcumin and were on this regimen until termination (promotion/progression stage). AOM was given to the animals s.c. at the beginning of 7 and 8 weeks of age at 15 mg/kg body weight.

tumors (25, 26, 28). Evidence also suggests that curcumin acts on pathways that may inhibit cell proliferation (19) and enhance apoptosis (29). In vitro studies by Hanif et al. (19) suggest that curcumin inhibits colon cancer cell proliferation, independent of its ability to inhibit PG synthesis. Furthermore, transformation of colorectal epithelium into adenomas and adenocarcinomas has been shown to be associated with progressive inhibition of apoptosis, suggesting that inhibition of apoptosis in colon carcinogenesis may contribute to tumor growth and promote neoplastic progression (30).

This study was designed to specifically investigate the chemopreventive efficacy and dose-response effect of curcumin when it is administered late in the premalignant stage, representing the promotion/progression phase of colon carcinogenesis in F344 rats. In addition, the effect of dietary curcumin on apoptosis in colon tumors was determined.

MATERIALS AND METHODS

Animals, Diets, and Carcinogen. Weanling male F344 rats were received from Charles River Breeding Laboratories (Kingston, NY). AOM was purchased weekly in our laboratory by adding curcumin at 0.2 and 0.6% levels instead of cornstarch (Table 1). The experimental and control diets were stored in a cold room.

Efficacy Study. The experimental protocols followed those detailed in our previous publications (27). Briefly, weanling male F344 rats were quarantined for 7 days and had access to modified AIN-76A control diet (Table 1). Following quarantine, at 5 weeks of age, all animals were randomly distributed by weight into the various experimental groups. As shown in Fig. 2, the points at which the animals received the test diets from 2 weeks before, during, and after carcinogen treatment to termination of the study were designated initiation and postinitiation stages, whereas promotion/progression stages represent the point at which the animals received test diets from 14 weeks after carcinogen treatment until the end of the study. Beginning at 5 weeks of age, groups of animals in the initiation and postinitiation study had access to either control diet or experimental diet containing 0.2% curcumin, whereas the rats for the assays testing efficacy during the promotion/progression stage received the control diet. At 7 weeks of age, all rats except those intended for vehicle treatment received s.c. injections of AOM at a dose rate of 15 mg/kg body weight, once weekly for 2 weeks. Rats in vehicle-treated control groups were injected with an equal volume of normal saline. The rats designated for the intervention during the promotion/progression stage and maintained on the control diet were then transferred to experimental diets containing 0.2 or 0.6% curcumin beginning 14 weeks after the second dose of AOM (Fig. 2). Our past experience on AOM-induced colon carcinogenesis suggests that the premalignant lesions in the colon would have developed by week 14 following carcinogen administration (26). This dietary regimen was continued until termination of the experiment 52 weeks after the last carcinogen treatment. Body weights were recorded every 2 weeks for the first 10 weeks and then every 4 weeks. At the scheduled termination, all animals were killed by CO2 euthanasia. After laparotomy, the entire gastrointestinal tract was resected and opened longitudinally, and the contents were flushed with normal saline. Colon tumors were recorded by gross observation using a dissection microscope. All other organs, including kidney, liver, and lungs were grossly examined under the dissection microscope for any abnormalities. For histopathological evaluation, colon tumors were fixed in 10% neutral buffered formalin, embedded in paraffin blocks, cut into multiple sections, and processed. The slides were stained with H&E and examined. The histological criteria used for classification of intestinal tumors were as described previously (24, 26). Upon termination of this study, more than 90% of the colon tumors had developed into adenocarcinomas that were classified as invasive or noninvasive. The invasive adenocarcinomas were mostly signet-ring mucinous types, invading the muscularis mucosa deep into the intestinal wall and beyond. The noninvasive adenocarcinomas were those growing outward toward the intestinal lumen without invasion of the muscularis mucosa. They were usually well-differentiated adenocarcinomas.

Table 1 Percentage composition of experimental semipurified diets

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>Control diet&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Experimental diets</th>
<th>% composition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Casemix</td>
<td>2.0</td>
<td>20.0</td>
<td></td>
</tr>
<tr>
<td>Ox-Methionine</td>
<td>0.3</td>
<td>0.3</td>
<td></td>
</tr>
<tr>
<td>Cornstarch</td>
<td>52.0</td>
<td>51.8 or 51.4</td>
<td></td>
</tr>
<tr>
<td>Dextrose</td>
<td>13.0</td>
<td>13.0</td>
<td></td>
</tr>
<tr>
<td>Corn oil</td>
<td>5.0</td>
<td>5.0</td>
<td></td>
</tr>
<tr>
<td>Alphacel</td>
<td>5.0</td>
<td>5.0</td>
<td></td>
</tr>
<tr>
<td>Mineral mix, AIN</td>
<td>3.5</td>
<td>3.5</td>
<td></td>
</tr>
<tr>
<td>Vitamin mix, AIN revised</td>
<td>1.0</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>Choline bitartrate</td>
<td>0.2</td>
<td>0.2 or 0.6</td>
<td></td>
</tr>
<tr>
<td>Curcumin&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0</td>
<td>0.2 or 0.6</td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> Adopted from the AIN reference diet (AIN-76A), with modification of the source of carbohydrate.

<sup>b</sup> Curcumin was added to the diets instead of cornstarch.
Detection of Apoptosis. Although apoptosis is characterized by DNA fragmentation, and the appearance of a “ladder” of nucleosomal-sized fragments on agarose gel electrophoresis has been used as a hallmark of apoptosis, DNA cleavage is not universally found in apoptosis (31). A ladder of DNA fragments has also been associated with necrosis in certain types of cells (32, 33). The gold standard for determination of apoptosis has been set through observation of characteristic morphological changes by electron microscopy (32, 34) or alternatively, by light microscopy (29, 35, 36). In this study, we examined the modulation of apoptosis by curcumin by quantifying the number of apoptotic cells in H&E-stained histological sections of colon tumors using light microscopy (29, 36). Apoptotic cells were identified by cell shrinkage, nuclear condensation, and formation of apoptotic bodies (29, 36). The light microscopic appearance of apoptotic bodies are quite diverse; most are round or roughly oval in shape. Apoptotic bodies vary in size, but they are a little smaller than the parent cells. Some apoptotic cells contain pyknotic chromatin, and some are devoid of a nuclear component (29, 36). The apoptotic index, which represents the percentage of cells exhibiting apoptosis, was determined by counting at least 300 cells in randomly chosen fields. All slides were scored by one person who was blinded to the experimental listing by means of code numbers.

Statistical Analysis. Data on body weights were compared among the levels of test agent using Student’s t test. The comparative colon tumor incidence (total number of colon tumor-bearing rats with respect to the total number of rats at risk) in the animals fed the control diet and those given experimental diets was analyzed using Armitage’s $\chi^2$ method. Tumor multiplicities (total number of colon tumors per animal) were calculated for each dietary group; the significance of the differences between results in groups on the control diet and experimental diets containing curcumin was analyzed using the unpaired Student’s $t$ test, accounting for unequal variance. The apoptotic index, which is expressed as the percentage of cells exhibiting apoptosis was analyzed by unpaired Student’s t test. Differences were considered statistically significant at $P < 0.05$.

RESULTS

General Observations. The body weights of rats who received the experimental diets containing 0.2% of curcumin starting from 2 weeks before, during, and after carcinogen treatment to termination of the study (initiation and postinitiation stages) and containing 0.2 or 0.6% curcumin beginning from 14 weeks after carcinogen treatment until the end of the study (promotion/progression stage) were comparable to weights of those fed the control diet only (Table 2). As expected, vehicle-treated animals in all groups weighed slightly more than those treated with AOM during the course of the study. In vehicle-treated rats, experimental diets containing curcumin did not produce any gross changes in any organs and, thus, showed no toxicity.

Tumor Data. There were no tumors among rats given vehicle only and maintained on control or experimental diets containing curcumin. The results, summarized in Table 3, indicate that administration of AOM induced adenomas and adenocarcinomas of the colon in ~9% and 82% of rats, respectively, who were fed the control diet. Because of long-term nature of this study (52 weeks), most of the colon tumors had become adenocarcinomas. Administration of 0.2% curcumin during the initiation and postinitiation stages (before, during and after carcinogen treatment) significantly inhibited the incidence of noninvasive adenocarcinomas (59% inhibition; $P < 0.05$), multiplicities of noninvasive adenocarcinomas (71% inhibition; $P < 0.01$), and total (noninvasive plus invasive) adenocarcinomas of the colon (34% inhibition; $P < 0.05$). The incidences of adenomas could not be compared among different groups because of low yield of this lesion. Administration of 0.2% curcumin during the promotion/progression stages (14 weeks after carcinogen treatment) also significantly inhibited the incidence of invasive adenocarcinomas of the colon (54% inhibition; $P < 0.05$). Although the inhibition of the incidences and multiplicities of noninvasive adenocarcinomas had reached 54 and 44%, respectively, in the rats given 0.2% curcumin during the promotion/progression stage, the differences were not statistically significantly ($P > 0.05$). It is noteworthy that administration of 0.2% curcumin during the promotion/progression stage significantly suppressed total colon tumor incidence and multiplicity (adenomas plus adenocarcinomas) as compared to results with the control diet.

### Table 2 Effect of dietary curcumin on body weights of male F344 rats

<table>
<thead>
<tr>
<th>Experimental group</th>
<th>No. of animals/group</th>
<th>Body weights (g) of animals on experimental diets</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Week 0</td>
</tr>
<tr>
<td>AOM-treated</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control diet</td>
<td>36</td>
<td>115 ± 10c</td>
</tr>
<tr>
<td>0.2% curcuminb</td>
<td>36</td>
<td>115 ± 8c</td>
</tr>
<tr>
<td>0.2% curcumin</td>
<td>36</td>
<td>115 ± 10c</td>
</tr>
<tr>
<td>0.6% curcumin</td>
<td>36</td>
<td>112 ± 9c</td>
</tr>
<tr>
<td>Experimental</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adenomas</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor Data.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Table 3 Effect of dietary curcumin on AOM-induced colon carcinogenesis in male F344 rats

<table>
<thead>
<tr>
<th>Experimental groups</th>
<th>Tumor incidence (% animals with tumors)</th>
<th>Tumor multiplicity (tumors/animal)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Adenomas</td>
<td>Noninvasive</td>
</tr>
<tr>
<td>Control diet</td>
<td>9</td>
<td>41</td>
</tr>
<tr>
<td>0.2% curcuminb</td>
<td>3 (67)b</td>
<td>17 (59)c</td>
</tr>
<tr>
<td>0.2% curcumin</td>
<td>3 (67)</td>
<td>19 (54)</td>
</tr>
<tr>
<td>0.6% curcumin</td>
<td>6 (33)</td>
<td>9 (76)c</td>
</tr>
</tbody>
</table>

- **Mean ± SD.**
- **Animals were administered curcumin beginning 2 weeks before, during, and after carcinogen treatment until termination of the study (initiation and postinitiation stages).**
- **Significantly different from control diet group by Student’s $t$ test, $P < 0.05$.**
- **Significantly different from control diet group by Student’s $t$ test, $P < 0.01$.**
- **Animals were administered curcumin beginning 14 weeks after carcinogen treatment until termination of the study (promotion/progression period).**
- **Significantly different from control diet group by Student’s $t$ test, $P < 0.05$.**
- **Significantly different from control diet group by Student’s $t$ test, $P < 0.01$.**
- **Significantly different from control diet group by Student’s $t$ test, $P < 0.001$.**
inhibition of colon tumors (P < 0.05). As expected, administration of 0.6% curcumin during the promotion/progression stage also significantly inhibited the incidence of noninvasive adenocarcinomas (78% inhibition; P < 0.01) and multiplicities of noninvasive (85% inhibition; P < 0.001) and invasive (45% inhibition; P < 0.05) adenocarcinomas of the colon. In addition, the incidences and multiplicities of total colon tumors (adenomas plus adenocarcinomas) were reduced when rats were given 0.6% curcumin (25 and 56% inhibition; P < 0.05 and P < 0.01). These results were analyzed using the linear correlation method for a dose-response effect. This analysis yielded the correlation coefficients (r) for multiplicity of adenocarcinomas with increasing levels of curcumin in the diet from 0 to 0.6%, suggesting a dose-dependent inhibition of colon tumors (P < 0.05): noninvasive adenocarcinomas, −0.97; invasive adenocarcinomas, −0.95; total adenocarcinomas, −0.97; and total tumors, −0.96.

**Apoptosis.** Having established the inhibition of colon carcinogenesis by dietary administration of 0.2% curcumin during the initiation and postinitiation stages and the effects by 0.2 and 0.6% curcumin given during the promotion/progression period, we investigated whether the inhibition of colon tumorigenesis by curcumin is associated with the modulation of apoptosis in the colon tumors. Results summarized in Table 4 indicate that continual administration of 0.2% curcumin during the initiation and postinitiation stages and feeding 0.2 and 0.6% curcumin during the promotion/progression period significantly increased the apoptotic index in the colon tumors as compared to that in tumors of rats given control diet (P < 0.05–P < 0.002).

**DISCUSSION**

This study is part of a large-scale evaluation of phytochemicals that have anti-inflammatory and antioxidant properties for their potential chemopreventive activities against colon carcinogenesis. The primary mission of these studies is to identify effective and safe chemopreventive agents that will facilitate the development of cancer-preventive strategies and their application in a clinical setting. Curcumin, a naturally occurring anti-inflammatory agent and antioxidant, has been shown to inhibit tumors in several organs, including 7,12-dimethylbenz[a]anthracene-induced and TPA-promoted skin tumors, benzo(a)pyrene-induced forestomach tumors, and AOM-induced intestinal tumors in mice (16, 17, 20), to cite a few. Recent studies from our laboratory and elsewhere that demonstrated an inhibitory effect of dietary curcumin when administered continuously during the initiation and postinitiation phases (20–24) provided a rationale for elucidating the efficacy of this agent against premalignant lesions during the promotion/progression stage of colon carcinogenesis.

The results of this study are in agreement with earlier investigations showing that dietary curcumin inhibits colon carcinogenesis when administered during the initiation and postinitiation periods (20, 23, 24). Our results also demonstrate for the first time that curcumin, a naturally occurring anti-inflammatory agent and antioxidant, given as a dietary supplement during promotion/progression period still inhibits tumorigenesis in the colon, suggesting that administration of curcumin may retard growth and/or development of existing neoplastic lesions in the colon. This also suggests the potential usefulness of this agent as a chemopreventive agent for individuals at high risk for colon cancer development, such as patients with polyps. This study further extends our earlier observations that synthetic NSAIDs, such as piroxicam and sulindac, given during the promotion/progression period protect against colon tumorigenesis in F344 rats (26, 37). Importantly, unlike synthetic NSAIDs curcumin does not produce any gastrointestinal toxicity, even at very high doses, which may provide advantage over synthetic agents.

With regard to the mode of chemopreventive action, curcumin exhibits a diverse array of metabolic, cellular, and molecular activities including inhibition of arachidonic acid formation and its further metabolism to eicosanoids. Studies from our laboratory have demonstrated that dietary curcumin significantly inhibits phospholipase A2 in colonic mucosa and tumors leading to the release of arachidonic acid from phospholipids, alters COX and LOX activities, and modifies PGE2 levels (24). Several lines of evidence also indicate that the mechanism of action of curcumin is not limited to PG inhibition. We had observed earlier that dietary curcumin inhibits LOX activity, and the production of the LOX metabolites, 5(S)-, 8(S)-, 12(S)-, and 15(S)-HETEs, in the colonic mucosa and in tumors (24). Importantly, LOX metabolites such as 12(S)-HETE have been shown to promote tumor cell adhesion, stimulate the spreading of tumor cells, and augment metastatic potential (38–40). Also, a positive correlation was observed between the levels of 8(S)-HETE and hyperproliferation and tumor development induced by TPA (41). Moreover, curcumin inhibits several mediators and enzymes involved in cell mitogenic signal transduction pathways (42) and activator protein-1 and nuclear factor k-B activation (43). Hanif et al. (19) provided evidence that curcumin inhibits cell proliferation and induces cell cycle changes in the colonic adenocarcinoma cell lines, HT-29 and HCT-15, and that this effect is independent of its ability to inhibit PG synthesis. Here, the inhibitory effects of curcumin administered during the promotion/progression stage of chemically induced carcinogenesis is associated with increased apoptosis, suggesting that increased cell death through apoptosis may be one of the mechanisms by which dietary curcumin affects this inhibition. The results of this and other studies support the concept that the capacity to induce apoptosis may be common to many chemopreventive agents (28, 44, 45). This has certainly been documented for NSAIDs and other agents that inhibit colon carcinogenesis, suggesting that cellular responses to these agents may contribute to chemopreventive effects (29, 35). The effects of curcumin demonstrated here resemble those of NSAIDs and thus seem to act strongly via inhibition of arachidonate metabolism and through reducing cell proliferation and inducing apoptosis.

In conclusion, the study described here demonstrates for the first time that dietary administration of curcumin during the promotion/progression stage of AOM induced colon carcinogenesis significantly inhibits tumor development in a dose-dependent manner and increases apoptosis in the colonic tumors. Similar levels of inhibition of colon tumorigenesis were achieved when 0.2% curcumin was administered either during initiation and postinitiation periods or promotion/progression stage, suggesting indirectly that most of chemopreventive efficacy of this agent is achieved during the promotion/progression phase in this model. Although the exact mechanisms of its chemopreventive action of curcumin remain to be elucidated, it would appear that modulation of tumorigenesis by this agent is associated
CHEMOPREVENTIVE EFFECT OF CURCUMIN

not only with the alteration of arachidonic acid metabolism through LOX and COX pathways (24) but also through mechanisms that are independent of eicosanoid metabolism, such as cell proliferation and apoptosis in the colon tumors.

ACKNOWLEDGMENTS

We thank Laura Nast for preparation of the manuscript, Ilse Hoffmann for editing the manuscript, and staff of the Research Animal Facility and Histopathology Facility for expert technical assistance. We thank Bob Kaskey of Gene Print (Bala Cynwyd, PA) for kindly providing curcumin.

REFERENCES

Chemopreventive Effect of Curcumin, a Naturally Occurring Anti-Inflammatory Agent, during the Promotion/Progression Stages of Colon Cancer

Toshihiko Kawamori, Ronald Lubet, Vernon E. Steele, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/59/3/597

Cited articles
This article cites 39 articles, 14 of which you can access for free at:
http://cancerres.aacrjournals.org/content/59/3/597.full#ref-list-1

Citing articles
This article has been cited by 35 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/59/3/597.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.